The rise of new weight-loss drugs has been a significant development in the medical field, offering hope to individuals struggling with obesity and related health issues. However, medical experts emphasize that these medications are not a quick fix and require long-term commitment for sustained success.

These new drugs, including GLP-1 receptor analogs like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), have demonstrated impressive results in clinical trials. Tirzepatide, in particular, has shown an average body weight reduction of up to 22.5% in adults with obesity or overweight, surpassing the results seen with semaglutide. These medications work by mimicking natural hormones that boost insulin production, curb appetite, and slow stomach-emptying, leading to a feeling of fullness.

Dr. V. Mohan, a Chennai-based diabetologist, notes that the evolution of weight-loss drugs has been decades in the making. Earlier drugs offered modest weight loss with significant side effects, but the new generation of GLP-1 receptor analogs has proven to be more effective.

Despite their effectiveness, these drugs are not meant to be stopped and restarted at will. Experts caution that patients who discontinue these medications may regain some or all of the lost weight. Obesity is a chronic disease, and these drugs do not offer a permanent cure. Long-term use is often necessary to maintain weight loss and manage the underlying condition.

Moreover, the long-term effects of these drugs are still under study. While clinical trials have shown promising results, more research is needed to fully understand the potential risks and benefits of prolonged use. Some studies also suggest that these drugs could reduce the risk of heart attacks and treat liver disease.

It's important to note that these medications work best when combined with a healthy eating plan and regular exercise. They can help manage hunger, cravings, and metabolic preservation, but lifestyle changes are crucial for long-term success.

The U.S. Food and Drug Administration (FDA) has approved several weight-loss drugs for long-term use, including orlistat (Xenical, Alli), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). However, these medications are not without side effects, and it's essential to discuss the potential risks and benefits with a healthcare professional before starting treatment.

Some doctors are also exploring the use of weight-loss drugs like Zepbound and Ozempic to help reduce cravings for illicit drugs and alcohol, though research on this application is still limited. This off-label use highlights the potential of these drugs to address addictive behaviors, but further studies are needed to confirm their effectiveness in this area.

In conclusion, new weight-loss drugs offer a promising tool in the fight against obesity, but they require a long-term commitment and should be used in conjunction with lifestyle modifications. Patients should consult with their healthcare providers to determine if these medications are right for them and to understand the potential risks and benefits of long-term use.